Test method of reaction of EPHX1 genotype based COPD to NAC

Abstract

The invention discloses a test method of reaction of EPHX1 genotype based COPD to NAC. The test method comprises the following steps: extracting a DNA by a phenol / chloroform method and sequencing, dividing COPD patients into slow and very slow gene activity group and a quick and normal gene activity group according to EPHX1 gene polymorphism, giving 600 mg Bid of NAC for 1 year to both groups, performing baseline measurement of pulmonary function parameters, completing SGRQ and 6MWT, measuring FVC and FEV1 at a follow-up day every 12 weeks, completingSGRQ and 6MWT in 24 and 48 weeks, and recording the number of acute exacerbationof COPD in one year. The data were statistically analyzed with SPSS. The results show that NAC is effective in the treatment of slow and very slow EPHX1 gene activityCOPD patients. The test method provided by the invention provides a solid basis for demonstrating the effect and mechanism of NAC based on pharmacogenomics in the individualized treatment of COPD.

Description

technical field [0001] The invention belongs to the technical field of pharmacogenomics, and in particular relates to a test method for NAC reaction of COPD based on EPHX1 genotype. Background technique [0002] It is well known that chronic obstructive pulmonary disease (COPD) is genetically related, and the genetic phenotypes and gene polymorphisms of various inflammatory factors, proteases, antiproteases, oxidoreductases, and detoxification enzymes involved in the pathogenesis of COPD determine the susceptibility to COPD. There is considerable evidence that increased oxidative stress is one of the key causes of COPD pathogenesis. In response to oxidative stress, the body has a complete set of enzymatic or non-enzymatic antioxidant systems to protect the body from the attack of oxidants. The most important oxidation-inhibiting enzymes known in the body mainly include glutathione S-transferase (GST), microsomal epoxide hydrolase (mEPH), heme oxygenase (hemeoxygenase, HO )...

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to provide a test method based on the response of EPHX1 genotype COPD to NAC, aiming to solve the problem that the existing technology cannot show whether N-acetylcysteine ​​​​antioxidative treatment is effective for COPD patients with different EPHX1 genotypes. The problem of different therapeutic effects

Images